"...it would have given Virax a nice boost had it gone through."
Agreed, stampeze. I would have expected 20pc lift in VHL shares.
Today the shares fell 10pc.
Transgene shares fell more, around 20pc before partially recovering.
I assume Transgene will consult manufacturing partner Sanofi about commercialization of TG-4010.
Meantime, I notice that the name Novartis is missing from today's announcement re the appointment of Dr Jason Smythe as a consultant on options for the Co-EX-GENE platform.
Perhaps VHL chairman, Dr Wayne Millen, will tomorrow confirm Novartis's decision not exercise its TG-4010 commercialization option. And comment on the implications.
VHL Price at posting:
0.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)